PhysIQ awarded patents for a game-changing deep net approach to estimating functional capacity daily from continuous wearable sensor data.

– PhysIQ’s adds yet another patent to its extensive portfolio on personalized physiology analytics powered by the similarity-based modeling machine learning approach.


PhysIQ continues to
receive recognition for the novelty and value of its technology with the
announcement of two new patent allowances by the US Patent & Trademark
Office on its core analytics in digital medicine. These analytics help power
PhysIQ’s machine learning and artificial
intelligence
(AI) approach to providing a platform for clinical markers of
health using continuous wearable
sensor data.

The physIQ platform is designed to allow healthcare providers to monitor high-utilization patients post-discharge in the home environment, and for use by clinical scientists in pharmacological and medical device trials to acquire digital biomarkers for efficacy and safety on subjects wearing sensors. The allowed patents add to an already large and venerable suite of patents that physIQ holds worldwide on its revolutionary health-monitoring technology platform.

System and Method for Improving Cardiovascular Health of Humans Patent

With the allowance of US Patent
Application 16/515,572 for “System and Method for Improving Cardiovascular
Health of Humans”, physIQ has received protection for its ground-breaking
approach to using deep neural networks to make estimates of cardiopulmonary
functional capacity from wearables. The physIQ deep net architecture does this
by analysis of the behavior of raw vital signs from human subjects wearing a
multivariate sensor throughout activities of daily living. The subject is
required only to wear the sensor and the result is computed passively.

In conventional medical practice, functional capacity of a human
subject is assessed in-clinic with an involved and expensive procedure such as
a Cardiopulmonary Exercise Test (CPET) to measure VO2Max, the maximum volume of
oxygen uptake of a person. VO2Max is an excellent measure of fitness as well as
the physiology of heart failure (HF), chronic obstructive pulmonary disease
(COPD), chemotherapy, and similar conditions or treatments. “Given the
difficulty of administering a conventional CPET,” said Matt Pipke, chief
technology officer, physIQ, “a low-tech 6-minute Walk Test (6MWT) is often
substituted, but it suffers from notorious inaccuracy. With the newly patented
approach, physIQ plans to be able to make reasonably accurate estimates of
VO2Max and related parameters daily directly from the sensor data with no
special activities or procedures.” PhysIQ is currently performing the
validation studies of this analytic in preparation for submission to FDA for
510(k) clearance.

Residual-Based Monitoring of Human Health Patent

The second patent allowance, for US
Patent Application 15/658,732 for “Residual-Based Monitoring of Human
Health”, is part of the large suite of patents issued to physIQ for its
personalized physiology modeling technology. This technology, for which physIQ
received FDA 510(k) clearance in 2015, learns the unique physiology of each
human subject from their own sensor data and can then provide a sensitive
dynamic baseline for the detection of early signs of change in the behavior of
monitored vital signs. Such change can provide warning of compensatory
physiological behavior in patients with chronic disease before the patient
decompensates into an acute care episode requiring emergency hospitalization.
Such early warning can be instrumental for clinicians to reach out to patients
at home and take steps to prevent the hospitalization. The approach can also be
used in clinical trials to strengthen the signal-to-noise ratio for
pharmacological or device efficacy evaluations in support of claims for overall
change in health and function.

PhysIQ’s data science team pioneered Similarity-Based Modeling,
the technology at the heart of the personalized approach, in other industries
like aviation and nuclear power while at SmartSignal Corp., which was acquired
by GE in 2011.

“We are currently providing our personalized modeling technology as part of a 400+ subject trial of an interventional device in heart failure, where we are will be supporting secondary efficacy claims,” said Chris Economos, chief commercial officer, physIQ, in reference to their partnership with Corvia Medical in a global phase 3 clinical trial.



Source link